FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120364536> ?p ?o ?g. }

• W3120364536 endingPage "588" @default.
• W3120364536 startingPage "573" @default.
• W3120364536 abstract "Resmetirom (MGL‐3196), a selective thyroid hormone receptor‐β agonist, was evaluated in a 36‐week paired liver biopsy study (NCT02912260) in adults with biopsy‐confirmed nonalcoholic steatohepatitis (NASH). The primary endpoint was relative liver fat reduction as assessed by MRI–proton density fat fraction (MRI‐PDFF), and secondary endpoints included histopathology. Subsequently, a 36‐week active treatment open‐label extension (OLE) study was conducted in 31 consenting patients (including 14 former placebo patients) with persistently mild to markedly elevated liver enzymes at the end of the main study. In patients treated with resmetirom (80 or 100 mg orally per day), MRI‐PDFF reduction at OLE week 36 was −11.1% (1.5%) mean reduction (standard error [SE]; P < 0.0001) and −52.3% (4.4%) mean relative reduction, P < 0.0001. Low‐density lipoprotein (LDL) cholesterol (−26.1% [4.5%], P < 0.0001), apolipoprotein B (−23.8% [3.0%], P < 0.0001), and triglycerides (−19.6% [5.4%], P = 0.0012; −46.1 [14.5] mg/dL, P = 0.0031) were reduced from baseline. Markers of fibrosis were reduced, including liver stiffness assessed by transient elastography (−2.1 [0.8] mean kilopascals [SE], P = 0.015) and N‐terminal type III collagen pro‐peptide (PRO‐C3) (−9.8 [2.3] ng/mL, P = 0.0004 (baseline ≥ 10 ng/mL). In the main and OLE studies, PRO‐C3/C3M (matrix metalloproteinase‐degraded C3), a marker of net fibrosis formation, was reduced in resmetirom‐treated patients (−0.76 [−1.27, −0.24], P = 0.0044 and −0.68, P < 0.0001, respectively). Resmetirom was well tolerated, with few, nonserious adverse events. Conclusion: The results of this 36‐week OLE study support the efficacy and safety of resmetirom at daily doses of 80 mg and 100 mg, used in the ongoing phase 3 NASH study, MAESTRO‐NASH (NCT03900429). The OLE study demonstrates a potential for noninvasive assessments to monitor the response to resmetirom from an individual patient with NASH." @default.
• W3120364536 created "2021-01-18" @default.
• W3120364536 creator A5016109793 @default.
• W3120364536 creator A5053405300 @default.
• W3120364536 creator A5058421287 @default.
• W3120364536 creator A5065016748 @default.
• W3120364536 creator A5075534723 @default.
• W3120364536 creator A5086072427 @default.
• W3120364536 creator A5091625375 @default.
• W3120364536 date "2021-01-04" @default.
• W3120364536 modified "2023-10-18" @default.
• W3120364536 title "Effects of Resmetirom on Noninvasive Endpoints in a 36‐Week Phase 2 Active Treatment Extension Study in Patients With NASH" @default.
• W3120364536 cites W1488770426 @default.
• W3120364536 cites W1964572117 @default.
• W3120364536 cites W2012868945 @default.
• W3120364536 cites W2046246972 @default.
• W3120364536 cites W2113440847 @default.
• W3120364536 cites W2325544658 @default.
• W3120364536 cites W2462595066 @default.
• W3120364536 cites W2580009538 @default.
• W3120364536 cites W2734724639 @default.
• W3120364536 cites W2759997926 @default.
• W3120364536 cites W2767673297 @default.
• W3120364536 cites W2770129291 @default.
• W3120364536 cites W2791708447 @default.
• W3120364536 cites W2908524400 @default.
• W3120364536 cites W2915480803 @default.
• W3120364536 cites W2953556757 @default.
• W3120364536 cites W2966600595 @default.
• W3120364536 cites W2985579744 @default.
• W3120364536 cites W2986883158 @default.
• W3120364536 cites W2993083975 @default.
• W3120364536 cites W2998643329 @default.
• W3120364536 cites W3005906362 @default.
• W3120364536 cites W3009945933 @default.
• W3120364536 cites W3028623918 @default.
• W3120364536 doi "https://doi.org/10.1002/hep4.1657" @default.
• W3120364536 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8034581" @default.
• W3120364536 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33860116" @default.
• W3120364536 hasPublicationYear "2021" @default.
• W3120364536 type Work @default.
• W3120364536 sameAs 3120364536 @default.
• W3120364536 citedByCount "61" @default.
• W3120364536 countsByYear W31203645362021 @default.
• W3120364536 countsByYear W31203645362022 @default.
• W3120364536 countsByYear W31203645362023 @default.
• W3120364536 crossrefType "journal-article" @default.
• W3120364536 hasAuthorship W3120364536A5016109793 @default.
• W3120364536 hasAuthorship W3120364536A5053405300 @default.
• W3120364536 hasAuthorship W3120364536A5058421287 @default.
• W3120364536 hasAuthorship W3120364536A5065016748 @default.
• W3120364536 hasAuthorship W3120364536A5075534723 @default.
• W3120364536 hasAuthorship W3120364536A5086072427 @default.
• W3120364536 hasAuthorship W3120364536A5091625375 @default.
• W3120364536 hasBestOaLocation W31203645361 @default.
• W3120364536 hasConcept C126322002 @default.
• W3120364536 hasConcept C126894567 @default.
• W3120364536 hasConcept C134018914 @default.
• W3120364536 hasConcept C142724271 @default.
• W3120364536 hasConcept C168563851 @default.
• W3120364536 hasConcept C203092338 @default.
• W3120364536 hasConcept C204787440 @default.
• W3120364536 hasConcept C27081682 @default.
• W3120364536 hasConcept C2775934546 @default.
• W3120364536 hasConcept C2777766500 @default.
• W3120364536 hasConcept C2778772119 @default.
• W3120364536 hasConcept C2779134260 @default.
• W3120364536 hasConcept C2779478299 @default.
• W3120364536 hasConcept C2780559512 @default.
• W3120364536 hasConcept C71924100 @default.
• W3120364536 hasConcept C90924648 @default.
• W3120364536 hasConceptScore W3120364536C126322002 @default.
• W3120364536 hasConceptScore W3120364536C126894567 @default.
• W3120364536 hasConceptScore W3120364536C134018914 @default.
• W3120364536 hasConceptScore W3120364536C142724271 @default.
• W3120364536 hasConceptScore W3120364536C168563851 @default.
• W3120364536 hasConceptScore W3120364536C203092338 @default.
• W3120364536 hasConceptScore W3120364536C204787440 @default.
• W3120364536 hasConceptScore W3120364536C27081682 @default.
• W3120364536 hasConceptScore W3120364536C2775934546 @default.
• W3120364536 hasConceptScore W3120364536C2777766500 @default.
• W3120364536 hasConceptScore W3120364536C2778772119 @default.
• W3120364536 hasConceptScore W3120364536C2779134260 @default.
• W3120364536 hasConceptScore W3120364536C2779478299 @default.
• W3120364536 hasConceptScore W3120364536C2780559512 @default.
• W3120364536 hasConceptScore W3120364536C71924100 @default.
• W3120364536 hasConceptScore W3120364536C90924648 @default.
• W3120364536 hasIssue "4" @default.
• W3120364536 hasLocation W31203645361 @default.
• W3120364536 hasLocation W31203645362 @default.
• W3120364536 hasLocation W31203645363 @default.
• W3120364536 hasOpenAccess W3120364536 @default.
• W3120364536 hasPrimaryLocation W31203645361 @default.
• W3120364536 hasRelatedWork W172225683 @default.
• W3120364536 hasRelatedWork W1975489439 @default.
• W3120364536 hasRelatedWork W2036698572 @default.
• W3120364536 hasRelatedWork W2086939368 @default.
• W3120364536 hasRelatedWork W2576488295 @default.

• next